๐ฐ Executive Master News
Page 21 - Executive Master News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Executive Master. Real-time updates on events, politics, business and more.
April 10, 2023
Singapore & New York, NY, April 10, 2023 -- Environmental Solutions Group Holdings Limited today announced that Mr. Lawrence Law, Chief Growth and Sustainability Officer and Director at ESGL... | April 10, 2023
April 6, 2023
Draft agenda and draft decisions for the Annual General Meeting of Telia Lietuva, AB shareholders to be held on 27 April 2023 proposed by the Board of the Company: 1. Information of the... | April 6, 2023
April 4, 2023
Current Dean Professor Ilian Mihov concludes deanship after a decade of transformation Fontainebleau (France), Singapore, Abu Dhabi, San Francisco, 4 A...
March 30, 2023
Annual General Meeting of 4 May 2023 Candidate Board members ... | March 30, 2023
March 30, 2023
/PRNewswire/ -- LightInTheBox Holding Co., Ltd. (NYSE: LITB) ("LightInTheBox" or the "Company"), a global online retail company that delivers products directly...
March 30, 2023
The University of Science and Technology of the Southern Philippines (USTP) System started exploring dual degree programs during a meeting together with Golden Gate University (GGU), March 23.
March 29, 2023
Crime shows to be the biggest issue for voters ahead of the Houston mayoral race 2023, according to a new poll by Ragnar Research.
March 24, 2023
MONT-SAINT-GUIBERT, Belgium, March 24, 2023 -- Celyad Oncology , a biotechnology company focused on innovative technologies for chimeric antigen receptor T-cell therapies, is pleased to announce... | March 24, 2023
March 24, 2023
24.03.2023 - Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD) (the โCompanyโ), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, is pleased to announce Georges Rawadi as its new Chief ... Seite 1
March 24, 2023
Regulatory News: Celyad Oncology (Euronext Nasdaq: CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, is pleased